Privacy, Pediatrics, and Policy

Wechsler,Jill;

News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Privacy, Pediatrics, and Policy

March 1, 2001

By Jill Wechsler, Pharm Exec’s Washington Correspondent

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-01-2001

Volume 0

Issue 0

FDA proposals for expanding the pediatric study program include tax incentives and }transferable exclusivity.}

Articles in this issue

Research: New Horizons

The Challenge of Prescription Drug Pricing

Earnings: Tough Times Ahead

Antigenics: Quest for a Cure

Outbreak: Anthrax Alarm

Patents: China on the Genome Map

Privacy, Pediatrics, and Policy

Lilly's International Family

Update: Punishment and Reprieve

Biotech: Down for the Count

Shortage: Vaccine Worries

Access: Success Story

Gateway to Japan

Surrounded

Related Content

Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031

Don Tracy, Associate Editor

September 11th 2024

Article

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs

September 6th 2024

Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Pharma Pulse 9/11/24: 2024 Veeva R&D and Quality Summit Coverage, Oracle’s Missteps in Cloud Computing & more

Miranda Schmalfuhs

September 11th 2024

Article

The latest news for pharma industry insiders.

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs

August 5th 2024

Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

Don Tracy, Associate Editor

September 10th 2024

Article

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.